Overview
News
Salaries
Products
People
Growth
Offices
Financials
Overview
Unlocking novel biomarkers to transform patient outcomes. Clinical-stage blood test platform for diagnosing and monitoring brain diseases.
News
GLX Analytix Strengthens Board with Experts in Blood-Based Neuroscience Diagnostics to Accelerate Market Adoption
Read more
Report
Wyss DxA Industrial Participant Program
As the industry-facing component of the Wyss Diagnostics Accelerator, the Industrial Participant Program is a collaboration hub between healthcare testing companies and the scientific and clinical community within the Wyss ecosystem that seeks to compress
Read more
Report
View in Journal
The GLX Signature platform detects schizophrenia from a blood sample and correlates with severity of psychosis
Read more
Report
